Recent findings demonstrated that a subset of papillary thyroid cancers (PTCs) is characterized by reduced expression of the von Hippel-Lindau (VHL) tumor suppressor gene, and that lowest levels associated with more aggressive PTCs. In the present study, the levels of the two VHL mRNA splicing variants, VHL-213 (V1) and VHL-172 (V2), were measured in a series of 96 PTC and corresponding normal matched tissues by means of quantitative RT-PCR. Variations in the mRNA levels were correlated with patients' clinicopathological parameters and disease-free interval (DFI).
Introduction
The von Hippel-Lindau (VHL) gene, located on chromosome 3p25-p26, consists of 3 exons (Latif et al. 1993) . Two different VHL mRNAs are generated because of differential splicing: the variant 1 (V1), including all three exons, and the variant 2 (V2), lacking exon 2 (Iliopolus et. 1998; Gnarra et al. 1994; Richards et al. 1996) . From the V1 mRNA, two VHL protein (pVHL) isoforms are synthesized due to alternate initiation sites of translation; the pVHL 213 , of about 30 kDa and containing 213 amino acids, and the pVHL 160 , of about 19 kDa and containing 160 amino acids (Schoenfeld et al. 1998) . The V2 mRNA variant encodes a protein of 172 amino acids lacking an amino-terminal pentameric acid repeat (β-domain), with a predicted molecular weight of about 19 kDa (pVHL 172 ) (Chesnel et al. 2015) .
The VHL gene is widely expressed in human tissues and acts as a tumor suppressor gene (Los et al. 1996) . Loss-of-function mutations cause the so-called VHL disease, an autosomal dominant disorder characterized by retinal angioma, cerebellar and spinal hemangioblastomas, clear-cell renal cell carcinoma (ccRCC), pheochromocytoma and pancreatic neuroendocrine tumor (Maher et al. 2011) . Besides, a number of sporadic cancers, including ccRCC, are strongly associated with VHL reduced expression and/or loss-of-function mutations (Gnarra et al. 1994; Cassol and Mete, 2015) . The best characterized pVHL function is ubiquitination followed by proteasome degradation of target proteins (Robinson and Ohh, 2014) . In particular, the pVHL forms a multiprotein complex with elongins B and C, cullin 2 and Rbx-1, which functions as a ubiquitinligating enzyme (E3 ligase). Within the complex pVHL is responsible for recognition of substrates, among which the members of the hypoxia-inducible factor α (HIFα) family (Robinson and Ohh, 2014) . In complex with HIFβ, HIFα act as transcription factors enhancing the expression of a variety of genes involved in the adaptive response to hypoxic condition and tumor progression as well, such as genes that promote neoangiogenesis (e.g. vascular endothelial growth factor, VEGF), energy metabolism (e.g. glucose transporter 1, GLUT1), erythropoiesis (e.g. erythropoietin, EPO), and cell survival (e.g. transforming growth factor-α, TGF-α) (Robinson and Ohh, 2014; Balamurugan, 2016) . In addition, VHL has been shown to affect several hypoxia-independent cellular functions, including extracellular matrix formation, spindle microtubule stability, cilia formation, epithelial-to-mesenchymal (EMT) transition, cell proliferation, apoptosis and DNA damage response (Robinson and Ohh, 2014) .
The pVHL region interacting with the elongins and Cul-2, named BC box, is coded by the third exon, thus all pVHL isoforms are able to form the E3 ligase complex (UniProtKB -P40337).
However, the binding with HIFα occurs via the β-domain, which is missing in the pVHL 172 Bonicalzi et al. 2001 ). Such domain is also essential for VHL interaction with the chaperonincontaining t-complex polypeptide 1 (CCT), a cytosolic molecular chaperone that assists in the folding of actin, tubulin and other cytosolic proteins. Even if the physiological role of pVHL 172 remains to be elucidated, it might be supposed that this isoform behaves, at least partially, as a VHL 213 antagonist, and possibly is endowed with new functions.
Some reports suggested that pVHL could play a role also in the progression of epithelial thyroid cancer (TC) (The Cancer Genome Atlas Research Network, 2014; Stanojevic et al. 2015; Hinze et al. 2000; Hunt et al. 2003) . The latter represents the most common endocrine malignancy accounting for roughly 1% of all human cancers, and its incidence has been increasing over the last decades mainly due to the improved ability to diagnose malignant transformation in small nonpalpable thyroid nodules (Jemal et al. 2009; Davies and Welch, 2006; Kinder, 2003; Patel and Shaha, 2006; Pasieka, 2003) . More than 90% of TC are differentiated thyroid carcinomas (DTC), 70-80% of which are represented by the papillary (PTC), and the remaining by the follicular (FTC) histotype (Nikiforov et al. 2009 ). Although derived from the same cell type, the DTC show specific Gospodarowicz et al. 2001; Passler et al. 2004; Castagna et al. 2011) . These parameters, however, are capable of providing only a rough prediction of the disease outcome placing patients with very different disease-specific progression and survival times within the same risk group.
Similarly, they fail to predict the risk of cancer relapse. Therefore, the identification of new prognostic molecular biomarkers able to testify tumor aggressiveness is required (Handkiewicz et al. 2010; Baldini et al. 2012; Ulisse et al. 2011) .
Although, to date, no loss-of-function mutations of the VHL gene in PTC tissues have been described, recent studies demonstrated that a subset of PTCs was characterized by low levels of VHL mRNA, which associated with more aggressive PTCs (The Cancer Genome Atlas Research Network, 2014; Stanojevic et al. 2015) .
In the present work, we measured the expression of the VHL gene, at mRNA level, in a case-study of 96 PTC tissues compared with their normal matched counterparts, and we evaluated the correlation of the VHL expression changes with clinicopathological parameters and disease-free interval.
Patients and Methods

Tissue samples, histology and patient's staging
Normal and matched tumor thyroid tissues were obtained from surgical specimens of 96 patients 
Determination of BRAF V600E mutation
Genomic DNA was extracted from the frozen tumor tissues using the DNeasy Blood and Tissues kit (QIAGEN, Milan, Italy) according to the manufacturer's protocol. The BRAF status of exon 15 was assessed by both direct sequencing and mutant allele-specific PCR amplification for the T to A M A N U S C R I P T
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6 substitution at nucleotide 1799 (V600E), using the procedure previously described (Barollo et al. 2010 ).
Extraction of mRNA and quantitative RT-PCR
Frozen normal and tumor thyroid tissues were homogenized with the ultra-turrax, and total RNA extracted applying the acid guanidinium thiocyanate-phenol-chloroform method (Chomczynsky and Sacchi, 1987) . The first cDNA strand was synthesized from 5 µg of RNA with M-MLV reverse transcriptase and anchored oligo(dT)23 primers (Sigma Chemicals Co. 
Statistical analysis
First, the Shapiro-Wilk test was used to check whether the mRNA data were normally distributed, and they were not. Thus, the non-parametric Mann-Whitney U-test was used to calculate the statistical significance of differences in the expression levels of VHL mRNA V1 and V2 in female vs male patients; in classical PTC variant vs other variants; in BRAF V600E mutated vs wild type PTC; in metastatic (N1) vs non-metastatic (N0) PTC; in T1-2 vs T3-4 tumor sizes; in TNM I-II vs III-IV stages; in presence or absence of recurrence. The correlation between V1 and V2 mRNAs, and between each of them and patient's age was evaluated by the Spearman's Rho test.
The VHL V1/V2 mRNA ratio comparison between normal and PTC tissues was performed with the Wilcoxon signed-rank test. To assess the independent association of patient's age, gender, tumor size, histological variants, BRAF status, lymph node metastases, stage and VHL mRNA variants with recurrences, the Cox regression with backward analysis was used. The impact of V1 or V2 expression on DFI was assessed by the Kaplan-Meier analysis combined with Mantel-Cox log-rank.
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For the latter, values were classified based on the following criteria: fold change > 1.2 as "increased"; fold change < 0.8 as "decreased"; 0.8 ≤ fold change ≤ 1.2 as unvaried. All the statistical analyses were carried out with the SPSS software (IBM, Armonk, NY, USA), and the results were considered significantly different if p values were lower than 0.05.
Results
VHL gene expression in papillary thyroid cancer (PTC) tissues
The analyses of V1 and V2 mRNA levels in PTC tissues, compared to their normal matched tissues, revealed that V1 mRNA was deregulated in 78 out of 96 PTC (81.3%), with an increase in 36 and a decrease in 42 cases ( Figure 1A ). The V2 mRNA was altered in 65 out of 96 PTC (67.7%), being up-regulated in 24 and down-regulated in 41 cases ( Figure 1B ). As reported in Figure 1C , mRNA levels of the two VHL variants positively correlated to each other (p<0.001). 
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Absolute quantification of the V1 and V2 mRNA copy number for each tumor and normal matched tissue showed that V1 mRNA copy number was higher compared to the V2 mRNA, with a median V1/V2 ratio of 3.95 in normal tissues (Figure 2 ). This ratio did not change significantly in PTC tissues, the median being 3.52 (p=0.655).
Figure 2: VHL V1/V2 mRNAs ratio in PTC and normal matched tissues.
BRAF V600E mutation and VHL expression in PTC tissues
To assess the effect of BRAF V600E mutation on VHL expression, we analyzed the V1 and V2 mRNA levels in 76 PTC tissues for which the analysis of BRAF gene status was available. Of these, 37 PTC (48.7%) harbored the BRAF V600E mutation while 39 (51.3%) had the wild type BRAF. The results, reported in table 2, showed that the BRAF V600E mutation did not affect VHL gene transcription in PTC tissues.
Prognostic relevance of VHL expression in PTC patients.
Among the clinicopathological parameters analyzed, a significant association emerged between tumor relapse and low levels of V2, and a similar trend (p=0.057), was recorded for V1 (Table 2) .
Moreover, increased V1 mRNA levels were found in male PTC tissues compared to the female ones (p=0.03). Cox regression analysis indicated that, among all the parameters considered, the presence of lymph node metastases at diagnosis represented a risk factor for tumor recurrences (Hazard Ratio, HR 9.37, p=0.003), while patients with increased V1 levels had a reduced risk of tumor recurrences (HR 0.18, p=0.025) . Kaplan-Mayer analysis demonstrated a significant correlation of both V1 and V2 mRNA levels with patients' disease-free interval (DFI). In figure 3 , panels A and increased, unvaried and decreased. Looking at the graphic of V1 mRNA, the trends for patients with unvaried and decreased values were very similar, so they were grouped together and compared against PTC patients with increased values. As shown in figure 3 (panel C), the returned p-value of log-rank test was 0.007. Regarding the V2 mRNA, PTC patients with unvaried or increased values had analogous DFI profiles ( figure 3, panel B) . When the latter were grouped together and compared to patients with decreased V2 mRNA levels, a significant difference (p=0.025) emerged ( figure 3, panel D) . Kaplan-Mayer analysis combined with Mantel-Cox log-rank statistical test, performed on 80 PTC patients followed-up from 5 to 141 months. Expression values of V1 and V2 VHL variants were classified as increased (fold change > 1.2), decreased (fold change < 0.8) or unvaried (0.8 ≤ fold change ≤ 1.2).
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Discussion
To date, relative few studies have attempted to investigate the effects of a deregulated VHL expression in DTC evolution (The Cancer Genome Atlas Research Network, 2014; Stanojevic et al. 2015; Hinze et al. 2000; Hunt et al. 2003) . Earlier immunohistochemical analyses demonstrated the presence of pVHL in normal thyroid follicular epithelium as well as in non-neoplastic lesions, and in DTC (Hinze et al. 2000) . Intriguingly, an inverse correlation between VHL expression and tumor differentiation was found, the pVHL being diminished in poorly differentiated TC, and very weak or undetectable in the most deadly type of TC, the anaplastic carcinoma (Hinze et al. 2003) .
However, no correlation between pVHL and VEGF proteins could be observed, suggesting a HIFα-independent role of pVHL in TC progression (Hinze et al. 2003) . Although no loss-of-function mutations of VHL have been described so far in PTC, one study reported loss of heterozygosis (LOH) at the VHL gene in FTC (Hunt et al. 2003) . These authors identified LOH in malignant but not in benign follicular tumors, and described a significant association between LOH and disease recurrence (Hunt et al. 2003) . In PTC, no LOH specific for the VHL gene has been identified so far;
however, different studies documented a variable LOH for the chromosomal region 3p where the VHL gene is located (Grebe et al. 1997; Rodrigues-Serpa et al. 2003) . In particular, Grebe and colleagues reported the presence of LOH on the chromosome 3p in 28.5% of PTC analyzed, while
Rodrigues-Serpa made the same observations in 40% of PTC (Grebe et al. 1997; Rodrigues-Serpa et al. 2003) . Since in our PTC series we found that both V1 and V2 mRNAs were downregulated in about 43% of cases, it may be speculated that haploinsufficiency is, at least in part, the cause of this reduction. Nevertheless, further studies will be required to prove this point.
More recently, Stanojevic and colleagues (2015) evaluated the status and expression of the VHL gene on a case study of 264 patients with PTC. No somatic mutations or evidence of VHL downregulation via promoter hypermethylation were found. However, low VHL mRNA levels strongly associated with older patient's age, advanced clinical stage, classical PTC variant, and multifocality (Stanojevic et al. 2015) . The authors noticed also a marginal influence of low VHL expression on disease-free interval (DFI) (p = 0.0502).
Over the years, most of the studies regarding VHL expression have been accomplished without distinguishing between isoforms. However, as mentioned above, the absence of part of the β-domain (aa 114-154) in pVHL 172 modifies the number of beta sheets in the structure, which is likely to cause altered protein activity and interactions (Schoenfeld et al. 1998 ). In our case study we sought to examine separately VHL isoforms in order to determine any differences in their expression profile that could be of relevance in thyroid tumor progression. Unfortunately, this approach implies the impossibility to discriminate isoforms at the protein level by means of M A N U S C R I P T
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immunohistochemistry, due to the lack of antibodies able to specifically identify the pVHL 172 . showed, however, the lack of any influence of the BRAF V600E mutation on VHL expression.
A significant association of low V2 mRNA levels with tumor recurrence was found, and a similar trend (p=0.057) appeared for the V1 variant. In agreement with this, multivariate analysis demonstrated that patients bearing increased levels of V1 mRNA had a reduced risk of tumor recurrences. In addition, the output of Kaplan-Meier analysis evidenced a shorter DFI for patients with reduced level of the V2 mRNA in tumor tissues, and for patients with either unvaried or diminished V1 mRNAs. The protective effect of the VHL gene in PTC patients is in line with its anti-oncogenic role extensively documented for kidney cancer.
The discrepancy between our observations and those reported by Stanojevic and colleagues (2015) may be explained by the fact that they analyzed VHL transcripts without distinguishing the two splicing variants, and they adopted a different method of relative quantification based on the comparison of PTC samples with each other, rather than with the normal matched samples.
Anyway, while taking into account the conflicting statistical results of the two studies, Stanojevic and colleagues pointed to an inverse correlation between VHL expression and PTC aggressive behaviour, essentially reflecting the overall indications emerged in our findings.
In conclusion, although the data here reported need to be confirmed by means of larger case-studies, they demonstrate that the expression of both VHL transcriptional variants is deregulated in the majority of PTC tissues. Their role(s) in PTC progression remains, however, to be clarified.
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Highlights
• Reduced expression of the VHL gene has been associated with more aggressive PTCs.
• Here we characterized the expression of the two VHL mRNA variants in PTC tissues.
• We showed that VHL gene expression is deregulated in the majority of PTC tissues.
• Of note is the protective role exerted by VHL transcripts against PTC recurrences.
